Latest news

Altis Labs Raises US $6 Million in Seed Funding Co-Led by Debiopharm and Benchstrength to Advance AI Platform for Clinical…

Debiopharm Shares Oncology Program Updates at ASCO 2023 for Novel WEE1 Inhibitor, and First-In-Class CA IX Theranostic Approach

Debiopharm Launches Phase 1 Research in Small Cell Lung Cancer with WEE1 inhibitor Debio 0123 to Outsmart DDR

Debiopharm Partners with Genedata to Digitalize Translational Research

Debiopharm Launches Phase 1/2 Combination Trial Investigating Brain-Penetrant Selective WEE1 Inhibitor for Brain Cancer Patients

Genialis Raises $13M to Build Clinical Biomarkers that Predict Patient Response

Debiopharm Announces Launch of the Phase 1/2 GaLuCi Study for its CA IX-Targeted Radiopharmaceutical Program

Iktos announces closing of € 15.5M series A round co-led by M Ventures and Debiopharm

Debiopharm extends their DNA damage repair footprint with new oncology pipeline entry